These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18294787)

  • 1. Applicability of DPI formulations for novel neurokinin receptor antagonist.
    Kumon M; Yabe Y; Kasuya Y; Suzuki M; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2008 May; 356(1-2):102-9. PubMed ID: 18294787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate.
    Kumon M; Machida S; Suzuki M; Kusai A; Yonemochi E; Terada K
    Chem Pharm Bull (Tokyo); 2008 May; 56(5):617-25. PubMed ID: 18451547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery.
    Onoue S; Yamamoto K; Kawabata Y; Hirose M; Mizumoto T; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):144-50. PubMed ID: 19703531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    J Control Release; 2004 May; 97(1):19-29. PubMed ID: 15147801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI).
    Telko MJ; Kujanpää J; Hickey AJ
    Int J Pharm; 2007 May; 336(2):352-60. PubMed ID: 17218072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable lactose-based dry powder formulations of low molecular weight heparin.
    Bai S; Gupta V; Ahsan F
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):97-104. PubMed ID: 19778265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices.
    Carter PA; Rowley G; Fletcher EJ; Stylianopoulos V
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1083-8. PubMed ID: 9876564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of high shear blending on alpha-lactose monohydrate.
    Bridson RH; Robbins PT; Chen Y; Westerman D; Gillham CR; Roche TC; Seville JP
    Int J Pharm; 2007 Jul; 339(1-2):84-90. PubMed ID: 17398047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
    Tsuchida H; Takahashi S; Nosaka E; Kuraya T; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 Oct; 596(1-3):153-9. PubMed ID: 18706408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Powder inhalation systems].
    Kohlhäufl M; Haidl P; Voshaar T; Häussinger K; Köhler D
    Dtsch Med Wochenschr; 2004 Sep; 129(39):2048-52. PubMed ID: 15386209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro deposition of the respirable fraction of dry powder inhalations determined by laser diffractometry and inertial impaction.
    Marques HM; Schmidt PC
    Pharmazie; 2002 Aug; 57(8):546-51. PubMed ID: 12227195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.
    Misaka S; Sato H; Yamauchi Y; Onoue S; Yamada S
    Eur J Pharm Sci; 2009 Jun; 37(3-4):469-76. PubMed ID: 19491038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental observations of dry powder inhaler dose fluidisation.
    Tuley R; Shrimpton J; Jones MD; Price R; Palmer M; Prime D
    Int J Pharm; 2008 Jun; 358(1-2):238-47. PubMed ID: 18457930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.